Gary Herbert Lyman | |
---|---|
Born | United States |
Nationality | American |
Occupation(s) | Hematologist, medical oncologist, academic and author |
Academic background | |
Education | Bachelor of Arts Doctor of Medicine Master of Public Health |
Alma mater | State University of New York at Buffalo Harvard University School of Public Health |
Academic work | |
Institutions | Fred Hutchinson Cancer Center Duke University |
Gary Herbert Lyman is an American academic hematologist, medical oncologist, and cancer researcher.[1]
Lyman is most known for his efforts in managing the adverse effects of cancer treatment including neutropenia and thrombosis among other toxicities along with establishing the clinical application of colony-stimulating factors and oral anticoagulants. He has also led efforts to address rising health care costs through national policy initiatives, clinical practice guidelines and the clinical integration of biosimilars and other approaches to reducing the financial burden of cancer on patients. His contributions extend to the development and validation of risk prediction models and the application of biomarkers for molecularly targeted therapies. Among his authored works are his publications in academic journals[2] as well as books such as Comprehensive geriatric oncology,[3] Breast cancer : Translational Therapeutic Strategies,[4] Cancer Supportive Care: Advances in Therapeutic Strategies,[5] and Hematopoietic Growth Factors in Oncology.[6] He is a Distinguished Emeritus member of the American Society of Hematology as well as the recipient of the Statesman Award from the American Society of Clinical Oncology.[7]